SciNeuro

formerly SciNeuro Pharmaceuticals

SciNeuro is a life sciences company in Shanghai, China, founded in 2020. It has raised $153.0M across 2 rounds, most recently a $53.0M Series B in December 2025.

Deciphering the Enigma of Brain Disease

Headquarters
Shanghai
Employees
11–50
Founded
2020
Business Model
B2B
Total Funding
$153.0M
Last Round
$53.0M Series BDec 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 3 investors for this company. The full record is or through the API.

About

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company transforming scientific discoveries into therapies for central nervous system diseases, with an expert team spanning discovery to clinical development in the US and China. Founded in late 2020 by Dr. Min Li, the company's pipeline addresses neurovascular inflammation, proteinopathy, and immune-driven neurodegeneration, including a blood-brain-barrier shuttle platform for CNS drug delivery. SciNeuro licensed a next-generation anti-amyloid antibody to Novartis for $165 million upfront and up to $1.5 billion in milestones, and separately raised $53 million to advance its pipeline.

Summary

It lists 11–50 employees. It has raised $153.0M in total across 2 rounds, most recently a $53.0M Series B round in Dec 2025. Investors include Lilly Asia Ventures, ARCH Venture Partners and General Atlantic.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries BDec 2025
$53.0M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
CertaraIPO

Global biosimulation software and services company accelerating drug development for 2,000+ bioph...

Radnor, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$1.3BDec 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SciNeuro on Indexed.vc
<a href="https://indexed.vc/companies/scineuro"><img src="https://indexed.vc/api/badge/company/scineuro" alt="SciNeuro on Indexed.vc" width="260" height="76" /></a>